Actively Recruiting
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
Led by Otsuka Pharmaceutical Co., Ltd. · Updated on 2025-03-21
1600
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
CONDITIONS
Official Title
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and older
- Patients with volume overload due to heart failure
You will not qualify if you...
- Known hypersensitivity to tolvaptan sodium phosphate or tolvaptan medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pharmacovigilance Department
Osaka, Japan, 540-0021
Actively Recruiting
Research Team
P
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here